3 Of My Top ISA Picks: AstraZeneca plc, Legal & General Group Plc And Burberry Group plc

These 3 stocks look set to post stellar returns: AstraZeneca plc (LON: AZN), Legal & General Group Plc (LON: LGEN) and Burberry Group plc (LON: BRBY).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investor sentiment in Burberry (LSE: BRBY) seems to be on the up, with the luxury lifestyle brand recording a rise in its share price of 11% since the turn of the year.

Clearly, at least some of this is due to reduced investor fear in recent weeks regarding the prospects for China, which remains a key market for Burberry. But with the company also having upbeat growth potential, it seems as though now could be a good time to buy it for the long term.

For example, Burberry is forecast to return to growth in the next financial year, with an 8% increase in earnings pencilled-in for the following year. And with the Chinese economy becoming increasingly consumer-focused, Burberry’s profit growth could be much higher over the medium-to-long term.

Certainly, the company’s shares seem to deserve a higher rating than their current price-to-earnings (P/E) ratio of 18.5, with Burberry’s high degree of customer loyalty providing it with a wide economic moat. Therefore, even though they’ve risen already this year, shares in Burberry seem to be worth considering for inclusion in an ISA.

Bight prospects

Similarly, Legal & General (LSE: LGEN) also appears to offer sound long-term total return prospects. It currently yields 6.2% and with dividends being covered 1.4 times by profit, there seem to be bright prospects for dividend growth. In fact, Legal & General is expected to increase shareholder payouts by 7.7% next year, which should easily beat inflation and provide the company’s shares with a positive catalyst.

As well as bright dividend prospects, Legal & General remains a solid value play. Its bottom-line growth forecasts of 9% this year and a further 6% next year don’t appear to be fully factored-in to its share price, with Legal & General currently trading on a P/E ratio of just 11.4. That’s significantly lower than the FTSE 100’s P/E ratio of around 13 and shows that while investor sentiment in Legal & General may be rather weak following its decline of 13% since the start of the year, it remains a very appealing buy for long-term investors.

Strong pipeline

On the topic of long term, AstraZeneca (LSE: AZN) is still on course to reverse its sales decline over the coming years. Investors hoping for a quick return via an acquisition for the pharmaceutical company may be somewhat disappointed though, since the prospects for this seem to have reduced since the US authorities announced their intention to close a tax loophole. However, with AstraZeneca’s own acquisition programme being in full swing, its pipeline appears to be more diversified and stronger than it has been for a considerable period of time.

This should boost the company’s top and bottom lines, thereby providing a positive catalyst for its share price over the long run. And with AstraZeneca yielding 5% despite having not raised dividends in the last five years, it remains a top notch income play which could begin to increase shareholder payouts as its profitability creeps upwards.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca, Burberry, and Legal & General Group. The Motley Fool UK has recommended AstraZeneca and Burberry. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£20,000 in savings? Here’s how I’d aim to turn that into passive income of £903 a month

Our writer shares one approach to passive income investing, spotlighting a quality FTSE 100 stock he recently added to his…

Read more »

Investing Articles

Great dividend stocks! Here’s the forecast for Associated British Food shares to 2027

Associated British Foods' shares have dropped in value this year. Does this present a dip-buying opportunity for dividend investors to…

Read more »

Investing Articles

Should I sell my FTSE All-Share index fund and buy a S&P 500 tracker instead?

Harvey Jones is wondering whether now is a good time to invest more money in the S&P 500, after a…

Read more »

Investing Articles

Should I buy dirt-cheap BT shares after the recent pullback?

BT shares were on the up but now they're sliding again after the board trimmed full-year guidance. Now Harvey Jones…

Read more »

Investing Articles

Up 28%, can the easyJet share price keep rising?

The easyJet share price has gained altitude over one year but plunged over five. Is now an attractive time for…

Read more »

British Isles on nautical map
Investing Articles

Should I buy more BAE Systems shares at 1,350p?

BAE Systems shares have had a fantastic run since early 2022, yet still don't appear overvalued. Is it now time…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

7% yield and a cheap valuation! Is this one of the best shares to buy this month?

Christopher Ruane has been looking for cheap shares to buy. This one has a 7% dividend yield, so is it…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Should I buy National Grid shares for the big dividend before it’s too late?

This year's price weakness has left National Grid shares on what looks like a tempting valuation. I hope it doesn't…

Read more »